Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20956151rdf:typepubmed:Citationlld:pubmed
pubmed-article:20956151lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:20956151lifeskim:mentionsumls-concept:C2709248lld:lifeskim
pubmed-article:20956151lifeskim:mentionsumls-concept:C1414864lld:lifeskim
pubmed-article:20956151lifeskim:mentionsumls-concept:C0079284lld:lifeskim
pubmed-article:20956151lifeskim:mentionsumls-concept:C0683597lld:lifeskim
pubmed-article:20956151pubmed:issue114lld:pubmed
pubmed-article:20956151pubmed:dateCreated2010-10-19lld:pubmed
pubmed-article:20956151pubmed:abstractTextEndothelial cells regulate vascular tone largely by the actions of endothelin-1. Endothelin-1 is a potent vasoconstrictor, with effects that are dependent on the receptors to which it binds as well as their location. Endothelin-1 dysregulation is implicated in pathological conditions, including those of the pulmonary vasculature and the kidney. In this review, we describe the physiology and actions of endothelin-1 in lung and renal tissues and discuss therapies that disrupt these interactions in disease states. We provide an overview of the current clinical progress of these targeted agents and provide perspectives on the treatment of pulmonary and renal diseases with endothelin receptor antagonists.lld:pubmed
pubmed-article:20956151pubmed:languageenglld:pubmed
pubmed-article:20956151pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20956151pubmed:citationSubsetIMlld:pubmed
pubmed-article:20956151pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20956151pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20956151pubmed:statusMEDLINElld:pubmed
pubmed-article:20956151pubmed:monthDeclld:pubmed
pubmed-article:20956151pubmed:issn1600-0617lld:pubmed
pubmed-article:20956151pubmed:authorpubmed-author:DavenportAAlld:pubmed
pubmed-article:20956151pubmed:authorpubmed-author:VachiéryJ-LJLlld:pubmed
pubmed-article:20956151pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20956151pubmed:day1lld:pubmed
pubmed-article:20956151pubmed:volume18lld:pubmed
pubmed-article:20956151pubmed:ownerNLMlld:pubmed
pubmed-article:20956151pubmed:authorsCompleteYlld:pubmed
pubmed-article:20956151pubmed:pagination260-71lld:pubmed
pubmed-article:20956151pubmed:meshHeadingpubmed-meshheading:20956151...lld:pubmed
pubmed-article:20956151pubmed:meshHeadingpubmed-meshheading:20956151...lld:pubmed
pubmed-article:20956151pubmed:meshHeadingpubmed-meshheading:20956151...lld:pubmed
pubmed-article:20956151pubmed:meshHeadingpubmed-meshheading:20956151...lld:pubmed
pubmed-article:20956151pubmed:meshHeadingpubmed-meshheading:20956151...lld:pubmed
pubmed-article:20956151pubmed:year2009lld:pubmed
pubmed-article:20956151pubmed:articleTitleThe endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses.lld:pubmed
pubmed-article:20956151pubmed:affiliationDept de Cardiologie, CUB-Hôpital Erasme, Brussels, Belgium. #Clinical Pharmacology Unit, Cambridge University, Cambridge, UK. jean-luc.vachiery@ulb.ac.belld:pubmed
pubmed-article:20956151pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20956151pubmed:publicationTypeReviewlld:pubmed